Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Expert Opinion on Investigational Drugs
|
February 26, 2025
Pepinemab: a SEMA4D antagonist for treatment of Huntington's and other neurodegenerative diseases
Andrew Feigin, Elizabeth E Evans, Terrence L Fisher, et al.
Molecular Cancer Therapeutics
|
February 7, 2015
Nonclinical Safety Evaluation of VX15/2503, a Humanized IgG4 Anti-SEMA4D Antibody
John E Leonard, Terrence L Fisher, Laurie A Winter, et al.
Journal of Neuroinflammation
|
August 6, 2022
Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity
Elizabeth E Evans, Vikas Mishra, Crystal Mallow, et al.
Cytometry. Part B, Clinical Cytometry
|
November 14, 2015
Saturation monitoring of VX15/2503, a novel semaphorin 4D-specific antibody, in clinical trials
Terrence L Fisher, Jennifer Seils, Christine Reilly, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
June 24, 2017
Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial
Christopher LaGanke, Lawrence Samkoff, Keith Edwards, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Drug Development
Elizabeth E Evans, Terrence L Fisher, Vikas Mishra, et al.
The Prostate
|
April 23, 2002
Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors
Terrence L Fisher, MaryAnn Nocera, Richard A Willis, et al.
Nature Medicine
|
October 4, 2022
Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial
Andrew Feigin, Elizabeth E Evans, Terrence L Fisher, et al.
Nature Medicine
|
August 8, 2022
Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial
Andrew Feigin, Elizabeth E Evans, Terrence L Fisher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 9, 2015
Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors
Amita Patnaik, Glen J Weiss, John E Leonard, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Expert Opinion on Investigational Drugs
|
February 26, 2025
Pepinemab: a SEMA4D antagonist for treatment of Huntington's and other neurodegenerative diseases
Andrew Feigin, Elizabeth E Evans, Terrence L Fisher, et al.
Molecular Cancer Therapeutics
|
February 7, 2015
Nonclinical Safety Evaluation of VX15/2503, a Humanized IgG4 Anti-SEMA4D Antibody
John E Leonard, Terrence L Fisher, Laurie A Winter, et al.
Journal of Neuroinflammation
|
August 6, 2022
Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity
Elizabeth E Evans, Vikas Mishra, Crystal Mallow, et al.
Cytometry. Part B, Clinical Cytometry
|
November 14, 2015
Saturation monitoring of VX15/2503, a novel semaphorin 4D-specific antibody, in clinical trials
Terrence L Fisher, Jennifer Seils, Christine Reilly, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
June 24, 2017
Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial
Christopher LaGanke, Lawrence Samkoff, Keith Edwards, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Drug Development
Elizabeth E Evans, Terrence L Fisher, Vikas Mishra, et al.
The Prostate
|
April 23, 2002
Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors
Terrence L Fisher, MaryAnn Nocera, Richard A Willis, et al.
Nature Medicine
|
October 4, 2022
Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial
Andrew Feigin, Elizabeth E Evans, Terrence L Fisher, et al.
Nature Medicine
|
August 8, 2022
Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial
Andrew Feigin, Elizabeth E Evans, Terrence L Fisher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 9, 2015
Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors
Amita Patnaik, Glen J Weiss, John E Leonard, et al.
Page
of 2